

Deconstructing Tumor Heterogeneity: The Stromal Perspective

September 19 – 20, 2019 NCI Shady Grove, Room TE 406

Workshop Agenda

Goals and objectives

Significant advances have recently been made towards understanding the role of immune cell-tumor interplay in either suppressing or promoting tumor growth, progression, and recurrence. However, much remains to be explored and revealed concerning the important roles of additional stromal cell types, including fibroblasts, endothelial cells, adipocytes, and the influence of the extracellular matrix. The overarching goal of this workshop is to build upon advances in tumor-immune interactions and to highlight and integrate the critical functions of these non-immune stromal cell types within the context of their contribution to tumor heterogeneity and its resultant impact on tumor initiation, progression, and resistance to therapy. The workshop will:

- Explore the concept of tumor supportive vs tumor suppressive stroma and how cellular composition and function may be altered during disease progression
- Discuss mechanisms by which the microenvironment may promote indolence or drive aggressiveness of early lesions
- Highlight emerging themes of stromal plasticity and tumor-stromal crosstalk
- Understand how spatial geography impacts stromal attributes and function
- Deliberate on the prognostic-therapeutic implications and potential vulnerabilities within the heterogeneous tumor microenvironment
- Facilitate discussion and collaboration among researchers investigating diverse aspects of stromal biology
- Identify current challenges and knowledge gaps in the field

Co-Chairs: Dr. Sheila Stewart, Washington University in St. Louis School of Medicine

Dr. Simon Hayward, NorthShore University Health System/University of Chicago

Day 1 September 19, 2019

07:30 Registration

08:00-08:30 Welcome and workshop overview

Program Objectives: Jeff Hildesheim, DCB, NCI

Opening Remarks: Dinah Singer, Deputy Director, NCI

Simon Hayward, NorthShore U Health System

University of Chicago

Session 1: Stromal-centric arbiters of tumor progression and suppression

Chair: Simon Hayward

08:30-08:55 Functional Heterogeneity of Fibroblasts and Type I Collagen

in Pancreatic Cancer

Raghu Kalluri, University of Texas, MD Anderson

08:55-09:20 Fibroblast Heterogeneity and Interactions with Periprostatic

Fat as Mediators of Prostate Cancer Progression

Simon Hayward, NorthShore University HealthSystem

University of Chicago

09:20-09:45 Age Against the Machine: How Aging Disrupts the

Homeostasis of the Stromal Microenvironment to Promote

Tumor Progression

Ashani Weeraratna, Johns Hopkins Bloomberg School

of Public Health

09:45-10:10 Mechanisms that Drive the Stromagenic Switch and CAF

Heterogeneity

Ellen Puré, University of Pennsylvania

10:10-10:35 Fibroblast Diversity in Pancreatic Cancer

David Tuveson, Cold Spring Harbor Laboratory

10:35-10:55 Discussion

10:55-11:15 Break

Session 2: Biology of early lesions: indolence vs aggressiveness

Chair: Sheila Stewart

11:15-11:40 Stromal Suppression of Tumor Growth in Tumors of

Endodermal Derivation

Phil Beachy, Stanford Institute for Stem Cell Biology &

Regenerative Medicine

11:40-12:05	Tissue Tumor Hotspot: Terroir for Tumorigenesis Wu-Min Deng, Tulane University School of Medicine
12:05-12:30	Computational Modeling of Single-Cell Data Identifies Cancer- Associated Fibroblasts Interactions with Tumor Cells to Drive the Progression of Colonic Adenomas Ken Lau, Vanderbilt University Medical Center
12:30-12:55	Mechanisms and Consequences of Pancreatic Cancer Stromal Evolution Mara Sherman, Oregon Health and Science University
12:55-13:15	Discussion
13:15-14:15	Lunch (on your own)

Session 3: Stromal plasticity and communication

Chair: Simon Hayward

14:15-14:40	New Players of the Stroma-Epithelium Crosstalk in Mesenchymal Colorectal Cancer Jorge Moscat, Sanford Burnham Institute
14:40-15:05	Deconstructing Adipogenic Niches with scRNA Sequencing: Implications for Stromal-Tumor Immune Cell Interactions James Granneman, Wayne State University
15:05-15:30	Acquisition of Tumor Heterogeneity Through Neoplastic Cell- Macrophage Fusion Melissa Wong, Oregon Health & Science University
15:30-15:40	Break
15:40-16:05	Applying Micro Scale Models to Explore Cancer Heterogeneity at Multiple Levels David Beebe, University of Wisconsin, Madison
16:05-16:30	Modeling Tumor/Microenvironment Interactions Using the Zebrafish Richard White, Memorial Sloan Kettering
16:30-16:55	Stromal Contributions to Ovarian Cancer Metastasis Ernst Lengyel, The University of Chicago
16:55-17:15	Discussion
Adjourn	
18:00-20:00	Dinner (on your own, organized by Chairs)

Day 2 September 20, 2019

Session 4: Geography and architecture matters

Chair: Sheila Stewart	
09:00-09:25	Endothelial Heterogeneity and Vascular Engineering Models Ying Zheng, University of Washington
09:25-09:50	Data Driven Annotation of Tumors and its Microenvironment by Transcriptome Analysis <i>In Situ</i> Joakim Lundeberg, KTH Royal Institute of Technology, Sweden
09:50-10:15	Cancer-Associated Fibroblast Subtypes in Control of Malignant Phenotypes Kristian Pietras, Lund University, Sweden
10:15-10:30	Break
10:30-10:55	The Microenvironment and Resistance to Targeted Therapies in Lung Cancer Katerina Politi, Yale School of Medicine
10:55-11:20	Cancer Associated Fibroblast Heterogeneity in Breast Cancer Ruth Scherz-Shouval, Weizmann Institute of Science
11:20-11:50	Discussion
11:50-13:00	Lunch (on your own)

Session 5: Prognostic and therapeutic implications of microenvironmental heterogeneity

Chair: Simon Hayward

13:00-13:25	Senescence Drives Chemotherapy-Induced Bone Loss Sheila Stewart, Washington University School of Medicine
13:25-13:50	Programming of Cancer Associated Fibroblasts Potentiate a Paracrine Signaling Loop that Confers Taxane Resistance Neil Bhowmick, Cedars-Sinai
13:50-14:15	Functional Heterogeneity of Pancreatic Cancer-Associated Fibroblast and Allied ECMs: Outcome Indicators Edna Cukierman, Fox Chase Cancer Center
14:15-14:40	Therapeutic Implications of Tumor Microenvironment Constituents as Drivers of Cancer Therapy Resistance Peter Nelson, Fred Hutchinson Cancer Center
14:40-15:05	Discussion

15:05-15:30 Wrap-up (state of the science, prioritization of the challenges ahead, and emerging directions)

Sheila Stewart, Workshop Co-Chair, Washington University Closing:

School of Medicine